Pharmacokinetic Study of Vivitrol in Healthy Participants

Opioid-use Disorder Clinical Trial

Official title:

A Bioequivalence Study Comparing Vivitrol and O'Neil Long Acting Naltrexone Implant (OLANI) in Healthy Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04716881
• Other study ID #: GM0019
• Secondary ID: UG3DA04772040619
• Status: Completed
• Phase: Phase 1
• Start date: January 25, 2021
• Est. completion date: April 4, 2022

Study information

• Verified date: February 2024
• Source: Go Medical Industries Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I, single-center, single arm, open-label study, to establish the pharmacokinetic (PK) parameters of Vivitrol 380 mg IM injection (IP), a US Food and Drug Administration (FDA) approved medication.

Description:

This is a Phase I, single-center, single arm, open-label study, to establish the PK parameters of Vivitrol 380 mg IM injection (IP), a US FDA approved medication. Participants will be healthy volunteers with no significant medical or mental health disorders, who have completed participation in clinical trial GM0017 (i.e. have received the OLANI treatment and have subsequently provided two consecutive plasma levels of naltrexone (NTX) <0.1ng/mL). This study will examine the PK profile of Vivitrol IM 380 mg over 6 doses for a treatment period of 196 days. Intense sampling will occur after the 1st and 6th dose of Vivitrol. Participants will be without a DSM 5 - Substance Related Disorders classification. Participants will be required to undergo a Naloxone Challenge Test (NCT) to confirm opiate naivety before administration of the IP. No randomization will occur.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: April 4, 2022
• Est. primary completion date: April 4, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 57 Years

Eligibility

Inclusion Criteria:

• Have completed GM0017 (i.e. been administered OLANI (3.6 gram) and provided two consecutive monthly blood samples of NTX below 0.1 ng/mL)
• Men or women between =18 and <58 years old Without DSM 5 - Substance Related Disorders classification; in sustained remission is not exclusionary
• Able and willing to comply with the requirements of the protocol
• Able and willing to provide written informed consent
• Willing to undergo an injection of NTX to allow for investigational drug administration in the intramuscular tissue
• Have an initial weight between 45.3 and 81.6 kilograms (inclusive) or have a BMI inclusive of 18.5 to 30.0.

Exclusion Criteria:

• Is currently on active NTX medication.
• Positive UDS at screening for illicit substances.
• Has a condition which requires treatment with opioid based medication.
• Has a known hypersensitivity to NTX.
• Is prone to skin rashes, irritation or has a skin condition such as recurrent eczema that is likely to impact the injection site area, or as determined by the evaluating physician.
• Demonstrates any abnormal skin tissue in the proposed injection area.
• Is pregnant or planning to be. Women need to have negative pregnancy test at screening. Women need to agree to practice an effective method of contraception throughout participation.
• Participant is breastfeeding or planning to be.
• Has a current significant neurological (including cognitive and psychiatric disorders),
• Any clinically important abnormal finding as determined by medical history, physical examination, ECG or clinical laboratory tests.
• Any additional condition(s) that in the investigator's opinion would prohibit the participant from completing the study or would not be in the best interest of the participant.
• ALT or AST >3 times the upper end of the laboratory normal range.
• Any methadone use 14 days prior to screening, and up to Study Day 0.
• Current DSM 5 diagnosis of schizophrenia, bipolar, anxiety, or depressive disorder, confirmed by MINI assessment, or currently treated with medications for anxiety or depression. Past history (in remission DSM 5 classification) of anxiety or depression is not exclusionary.
• Any elevated risk for suicide measured using the Columbia Suicide Severity Rating Scale, endorsing any of the items in the past month (C-SSRS, Lifetime)
• Is participating or intending to participate in any other clinical trial during the duration of this study.
• Is allergic to any of the ingredients in Vivitrol or the diluent used to mix Vivitrol (i.e. carboxymethylcellulose sodium, polysorbate 20, sodium chloride, sodium hydroxide and hydrochloric acid as pH adjusters, in water for injection).

Related Conditions & MeSH terms

• Opioid-Related Disorders
• Opioid-use Disorder

Intervention

Drug:
• Naltrexone 380 MG
Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days

Locations

Country	Name	City	State
United States	Columbia University Medical Center	New York	New York

Sponsors (5)

Lead Sponsor	Collaborator
Go Medical Industries Pty Ltd	Clinilabs, Inc., Columbia University, National Institute on Drug Abuse (NIDA), New York State Psychiatric Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median Cmax of Naltrexone (After 1st Dose)	Single-dose PK measurement of the maximum observed plasma naltrexone concentration (Cmax) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median Tmax of Naltrexone (After 1st Dose)	Single-dose PK measurement of the time to maximum plasma naltrexone concentration (Tmax) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median AUC0-inf of Naltrexone (After 1st Dose)	Single-dose PK measurement of the area under the plasma concentration-time curve for naltrexone from time 0 extrapolated to infinity (AUC0-inf) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median Ctrough of Naltrexone (After 1st Dose)	Single-dose PK measurement of naltrexone concentration at the end of the dosing interval (Ctrough) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median Cmax of 6ß-naltrexol (After First Dose)	Single-dose PK measurement of the maximum observed plasma 6ß-naltrexol concentration (Cmax) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median Tmax of 6ß-naltrexol (After 1st Dose)	Single-dose PK measurement of the time to maximum plasma 6ß-naltrexol concentration (Tmax) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median AUC0-inf of 6ß-naltrexol (After 1st Dose)	Single-dose PK measurement of the area under the plasma concentration-time curve for 6ß-naltrexol from time 0 extrapolated to infinity (AUC0-inf) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median Ctrough of 6ß-naltrexol (After 1st Dose)	Single-dose PK measurement of 6ß-naltrexol concentration at the end of the dosing interval (Ctrough) after dosing on Day 0	1st dose: Day 0 (predose), 1, 2, 4, 8, 12 hours, 24 hours (Day 1), Days 1.5, 1.75, 2, 3, 5, 7, 10, 14, 17, 21, 24, and 28.
Primary	Median Cmax of Naltrexone (After 6th Dose)	PK measurement of the maximum observed plasma naltrexone concentration (Cmax) after 6th dose on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Primary	Median Tmax of Naltrexone (After 6th Dose)	PK measurement of the time to maximum plasma naltrexone concentration (Tmax) after dosing on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Primary	Median AUC0-inf of Naltrexone (After 6th Dose)	PK measurement of the area under the plasma concentration-time curve for naltrexone from time 0 extrapolated to infinity (AUC0-inf) after dosing on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Primary	Median Ctrough of Naltrexone (After 6th Dose)	PK measurement of naltrexone concentration at the end of the dosing interval (Ctrough) after dosing on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Primary	Median Cmax of 6ß-naltrexol (After 6th Dose)	PK measurement of the maximum observed plasma 6ß-naltrexol concentration (Cmax) after dosing on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Primary	Median Tmax of 6ß-naltrexol (After th Dose)	PK measurement of the time to maximum plasma 6ß-naltrexol concentration (Tmax) after dosing on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Primary	Median AUC0-inf of 6ß-naltrexol (After 6th Dose)	PK measurement of the area under the plasma concentration-time curve for 6ß-naltrexol from time 0 extrapolated to infinity (AUC0-inf) after dosing on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Primary	Median Ctrough of 6ß-naltrexol (After 6th Dose)	PK measurement of 6ß-naltrexol concentration at the end of the dosing interval (Ctrough) after dosing on Day 140	6th dose: Day 140 (1, 2, 4, 8 & 12 hours), 141, 141.5, 141.75, 142, 143, 145, 147, 150, 154, 157, 161, 164, 168, 182 and 196
Secondary	Adverse Events (AEs)	Proportion of participants reporting AEs	Up to Day 196
Secondary	Naltrexone Accumulation Ratio (AR) for Cmax	The naltrexone AR was determined for Cmax by dividing the PK parameter for Dose 6 by the PK parameter for Dose 1.	196 days after the 6th dose
Secondary	Naltrexone Accumulation Ratio (AR) for Ctrough	The naltrexone AR was determined for Crough by dividing the PK parameter for Dose 6 by the PK parameter for Dose 1.	196 days after the 6th dose
Secondary	Naltrexone Accumulation Ratio (AR) for AUC0-inf	The naltrexone AR was determined for AUC0-inf by dividing the PK parameter for Dose 6 by the PK parameter for Dose 1.	196 days after the 6th dose
Secondary	6ß-naltrexol Accumulation Ratio (AR) for Cmax	The 6ß-naltrexol AR was determined for Cmax by dividing the PK parameter for Dose 6 by the PK parameter for Dose 1.	196 days after the 6th dose
Secondary	6ß-naltrexol Accumulation Ratio (AR) for Ctrough	The 6ß-naltrexol AR was determined for Ctrough by dividing the PK parameter for Dose 6 by the PK parameter for Dose 1.	196 days after the 6th dose
Secondary	6ß-naltrexol Accumulation Ratio (AR) for AUC0-inf	The 6ß-naltrexol AR was determined for AUC0-inf by dividing the PK parameter for Dose 6 by the PK parameter for Dose 1.	196 days after the 6th dose